Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2011

01-04-2011 | Review

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis

Authors: Zoe E Betteridge, Harsha Gunawardena, Neil J McHugh

Published in: Arthritis Research & Therapy | Issue 2/2011

Login to get access

Abstract

Autoantibodies targeting intracellular proteins involved in key processes are detected in patients with idiopathic inflammatory myopathies. These myositisspecific autoantibodies have been increasingly demonstrated to correlate with distinct clinical phenotypes within the myositis spectrum. This review highlights the clinical associations of the myositisspecific autoantibodies, with particular attention to the recently identified and characterized novel myositis autoantibodies: p155/140, p140 (MJ), CADM-140 (MDA5), SAE, and 200/100.
Appendix
Available only for authorised users
Literature
1.
Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975, 292: 344-347. 10.1056/NEJM197502132920706.CrossRefPubMed
2.
Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975, 292: 403-407. 10.1056/NEJM197502202920807.CrossRefPubMed
3.
Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y: Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995, 22: 668-674.PubMed
4.
Gunawardena H, Betteridge ZE, McHugh NJ: Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009, 48: 607-612. 10.1093/rheumatology/kep078.CrossRef
5.
Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W, Isenberg DA, Oddis CV, Silman AJ, Ollier WE, Cooper RG, UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC): In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006, 8: R13-10.1186/ar1862.PubMedCentralCrossRefPubMed
6.
Vancsa A, Gergely L, Ponyi A, Lakos G, Nemeth J, Szodoray P, Danko K: Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine. 2010, 77: 125-130. 10.1016/j.jbspin.2009.08.008.CrossRefPubMed
7.
Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, Wener MH, Pachman LM, Plotz PH: A broadened spectrum of juvenile myositis. Myositisspecific autoantibodies in children. Arthritis Rheum. 1994, 37: 1534-1538. 10.1002/art.1780371019.CrossRefPubMed
8.
Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, Nagai S, Umehara H, Mimori T: Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006, 39: 233-241. 10.1080/08916930600622884.CrossRefPubMed
9.
Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP: Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007, 56: 3125-3131. 10.1002/art.22865.CrossRefPubMed
10.
Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, Genth E, Mierau R, Gromnica-Ihle E: Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations. Clin Rheumatol. 2000, 19: 371-377. 10.1007/s100670070030.CrossRefPubMed
11.
Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, Song YW, Mimori T, Targoff IN: Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 2007, 56: 1295-1303. 10.1002/art.22506.CrossRefPubMed
12.
Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, Saito Y, Matsushita Y, Kawara S, Yasui M, Seishima M, Ozaki S, Kuwana M, Ogawa F, Sato S, Takehara K: Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007, 34: 1012-1018.PubMed
13.
Sato S, Kuwana M, Hirakata M: Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford). 2007, 46: 842-845. 10.1093/rheumatology/kel435.CrossRef
14.
Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, Loy AC, Chan EK, Reeves WH, Satoh M: Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 2006, 54: 2004-2009. 10.1002/art.21883.CrossRefPubMed
15.
Hashish L, Trieu EP, Sadanandan P, Targoff IN: Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (abstract). Arthritis Rheum. 2005, 52: S312-10.1002/art.20784.CrossRef
16.
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N: Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007, 46: 1005-1008. 10.1093/rheumatology/kem045.CrossRef
17.
Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005, 201: 591-601. 10.1084/jem.20041367.PubMedCentralCrossRefPubMed
18.
Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med. 1999, 190: 815-826. 10.1084/jem.190.6.815.PubMedCentralCrossRefPubMed
19.
Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, Rosen A, Casciola-Rosen LA: Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum. 2007, 56: 2729-2739. 10.1002/art.22790.CrossRefPubMed
20.
Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Härtlein M, Kron M, Yang D, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002, 196: 781-791. 10.1084/jem.20020186.PubMedCentralCrossRefPubMed
21.
Barbasso Helmers S, Englund P, Engström M, Ahlin E, Fathi M, Janciauskiene S, Heimbürger M, Rönnelid J, Lundberg IE: Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009, 60: 2524-2530. 10.1002/art.24683.CrossRefPubMed
22.
Eloranta ML, Barbasso HS, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE: A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007, 56: 3112-3124. 10.1002/art.22860.CrossRefPubMed
23.
Targoff IN, Reichlin M: The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985, 28: 796-803. 10.1002/art.1780280711.CrossRefPubMed
24.
Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED: Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol. 1996, 23: 1794-1797.PubMed
25.
Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, McCann LJ, Varsani H, Dunphy J, North J, Davidson JE, Juvenile Dermatomyositis Research Group (JDRG): HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007, 46: 1786-1791. 10.1093/rheumatology/kem265.CrossRef
26.
Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA, Reveille JD, Arnett FC, Targoff IN, Miller FW: Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009, 60: 2499-2504. 10.1002/art.24702.PubMedCentralCrossRefPubMed
27.
Burd CJ, Kinyamu HK, Miller FW, Archer TK: UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem. 2008, 283: 34976-34982. 10.1074/jbc.M805383200.PubMedCentralCrossRefPubMed
28.
Wang HB, Zhang Y: Mi2, an auto-antigen for dermatomyositis, is an ATPdependent nucleosome remodeling factor. Nucleic Acids Res. 2001, 29: 2517-2521. 10.1093/nar/29.12.2517.PubMedCentralCrossRefPubMed
29.
Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A: Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009, 60: 3784-3793. 10.1002/art.24977.PubMedCentralCrossRefPubMed
30.
Kashiwagi M, Morgan BA, Georgopoulos K: The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development. 2007, 134: 1571-1582. 10.1242/dev.001750.CrossRefPubMed
31.
Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54: 3682-3689. 10.1002/art.22164.CrossRefPubMed
32.
Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K: Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007, 46: 25-28. 10.1093/rheumatology/kel161.CrossRef
33.
Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG: The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007, 66: 1345-1349. 10.1136/ard.2006.068502.PubMedCentralCrossRefPubMed
34.
Selva-O'Callaghan A, Trallero-Araguás E, Grau-Junyent JM, Labrador-Horrillo M: Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol. 2010, 22: 627-632.CrossRefPubMed
35.
Gunawardena H, North J, Wedderburn L, Davidson J, Betteridge ZE, Dunphy J, Chinoy H, Cooper RG, McHugh NJ: Clinical associations of anti-p155/140 autoantibodies in adult and juvenile dermatomyositis (abstract). Ann Rheum Dis. 2007, 66: S68-
36.
Espada G, Maldonado Cocco JA, Fertig N, Oddis CV: Clinical and serologic characterization of an argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009, 36: 2547-2551. 10.3899/jrheum.090461.CrossRefPubMed
37.
Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarsai T, Miller FW: Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis (abstract). Arthritis Rheum. 2006, 54: S518-10.1002/art.22164.CrossRef
38.
Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S: FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 2009, 136: 123-135. 10.1016/j.cell.2008.10.051.CrossRefPubMed
39.
Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T: Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010, 49: 1726-1733. 10.1093/rheumatology/keq153.CrossRef
40.
Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, Nishikawa T, Oddis CV, Ikeda Y: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005, 52: 1571-1576. 10.1002/art.21023.CrossRefPubMed
41.
Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009, 60: 2193-2200. 10.1002/art.24621.CrossRefPubMed
42.
Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, Kawabata D, Ohmura K, Usui T, Fujii T, Okawa K, Mimori T: The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti- CADM-140 antibody. Rheumatology (Oxford). 2010, 49: 433-440. 10.1093/rheumatology/kep375.CrossRef
43.
Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Kamachi M, Nakamura H, Ida H, Origuchi T, Ishimoto H, Mukae H, Kuwana M, Kohno S, Takehara K, Sato S, Eguchi K: Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009, 38: 263-267. 10.1080/03009740802687455.CrossRefPubMed
44.
Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco MA: Clinical and serological characterisation of the anti-MJ antibody in childhood myositis (abstract). Arthritis Rheum. 1997, 40: S139-
45.
Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV: Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum. 2007, 56: S787-
46.
Kimura Y, Sakai F, Nakano O, Kisaki O, Sugimoto H, Sawamura T, Sadano H, Osumi T: The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem. 2002, 277: 20611-20617. 10.1074/jbc.M201440200.CrossRefPubMed
47.
Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, Cooper RG, Oddis CV, Ramanan AV, Davidson JE, McHugh NJ, Juvenile Dermatomyositis Research Group, UK and Ireland: Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009, 60: 1807-1814. 10.1002/art.24547.PubMedCentralCrossRefPubMed
48.
Betteridge ZE, Gunawardena H, Chinoy H, Vencovsky J, Allard S, Gordon PA, Cooper RG, McHugh NJ: Clinical associations of anti-p140 autoantibodies in adult myositis. Ann Rheum Dis. 2010, 69 (Suppl 3): 127-
49.
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N: Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007, 56: 3132-3137. 10.1002/art.22862.CrossRefPubMed
50.
Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ, UK Adult Onset Myositis Immunogenetic Collaboration: Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann Rheum Dis. 2009, 68: 1621-1625. 10.1136/ard.2008.097162.CrossRefPubMed
51.
Reeves WH, Nigam SK, Blobel G: Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA. 1986, 83: 9507-9511. 10.1073/pnas.83.24.9507.PubMedCentralCrossRefPubMed
52.
Targoff IN, Johnson AE, Miller FW: Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990, 33: 1361-1370. 10.1002/art.1780330908.CrossRefPubMed
53.
Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG: Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006, 65: 1635-1638. 10.1136/ard.2006.052191.PubMedCentralCrossRefPubMed
54.
Miller T, Al-Lozi MT, Lopate G, Pestronk A: Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002, 73: 420-428. 10.1136/jnnp.73.4.420.PubMedCentralCrossRefPubMed
55.
Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grøndal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001, 60: 116-123. 10.1136/ard.60.2.116.PubMedCentralCrossRefPubMed
56.
Rouster-Stevens KA, Pachman LM: Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008, 35: 927-929.PubMed
57.
Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL: A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010, 62: 2757-2766. 10.1002/art.27572.PubMedCentralCrossRefPubMed
58.
Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, Zen M, Vattemi GA, Lundberg IE, Doria A: Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford). 2010, 49: 2370-2374. 10.1093/rheumatology/keq281.CrossRef
59.
Vencovsky J, Lundberg IE, Patterson E, Ekholm L, Dankø K, Putova I, Charles PJ: Myositis associated autoantibodies detected using a novel recombinant protein blotting: clinical associations. Ann Rheum Dis. 2010, 69 (Suppl 3): 425-
Metadata
Title
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis
Authors
Zoe E Betteridge
Harsha Gunawardena
Neil J McHugh
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3275

Other articles of this Issue 2/2011

Arthritis Research & Therapy 2/2011 Go to the issue

Review

Chromatin as a target antigen in human and murine lupus nephritis

Research article

Reproduction of overall spontaneous pain pattern by manual stimulation of active myofascial trigger points in fibromyalgia patients

Research article

Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoarthritic and normal cartilage

Review

Update on peripheral mechanisms of pain: beyond prostaglandins and cytokines

Research article

Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study

Editorial

Chemerin/ChemR23 pathway: a system beyond chemokines

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits